Test Price
2,800 AED✅ Home Collection Available
GBA Gene Lewy Body Dementia Susceptibility Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين GBA للكشف عن القابلية للإصابة بخرف أجسام ليوي في الإمارات | 2800 درهم إماراتي | معتمد من هيئة الصحة بدبي وفق معايير 2026
Executive Summary — ملخص تنفيذي
Diagnostic Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO 9001:2015 Accredited NGS Processing (Cert: INT/EGQ/2509DA/3139). Our laboratory employs Next-Generation Sequencing with proprietary bioinformatics pipelines validated against 2026 AI Medical Datasets, ensuring clinically actionable results for GBA variant classification in Lewy Body Dementia susceptibility assessment.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection, with VIP Mobile Phlebotomy services available across all seven Emirates from 8:00 AM to 11:00 PM, seven days a week.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by qualified genetic counselors, ensuring patients and referring physicians fully understand the clinical implications of identified GBA variants.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We interface with all major UAE health insurers for seamless pre-authorization.
ضمان الدقة التشخيصية: حساسية تشخيصية بنسبة 99.9% مُحقَّقة عبر معالجة بتقنية التسلسل الجيني من الجيل التالي (NGS) ومعتمدة وفق شهادة الأيزو 9001:2015 (رقم الشهادة: INT/EGQ/2509DA/3139).
الخدمات اللوجستية المتميزة: خدمة منزلية مدفوعة لجمع العينات وفق معايير سلسلة التبريد المعتمدة دولياً، مع خدمة سحب دم متنقلة (VIP) متاحة يومياً من الثامنة صباحاً حتى الحادية عشرة مساءً في جميع الإمارات.
الإرشاد السريري: استشارة سريرية هاتفية بعد صدور النتائج يقدمها مستشارون وراثيون مؤهلون لضمان فهم دقيق للنتائج الجينية والآثار السريرية المترتبة.
التأمين الصحي: التحقق المباشر من تغطية التأمين عبر الواتساب على الرقم +971 54 548 8731.
Overview
The GBA Gene Lewy Body Dementia Susceptibility Genetic Test is a comprehensive molecular diagnostic assay that analyzes the full coding sequence and splice-site regions of the GBA (glucosylceramidase beta) gene using Next-Generation Sequencing technology. Mutations in the GBA gene represent the most significant common genetic risk factor for Lewy Body Dementia (LBD), with heterozygous pathogenic variants conferring a 2- to 8-fold increased lifetime risk. This test is clinically indicated for individuals with a family history of LBD, Parkinson's disease, or Gaucher disease, as well as for patients presenting with prodromal symptoms including REM sleep behavior disorder, autonomic dysfunction, and fluctuating cognition.
تحليل جين GBA للكشف عن القابلية الوراثية للإصابة بخرف أجسام ليوي هو فحص جزيئي تشخيصي شامل يُحلل التسلسل الكامل للمناطق المشفّرة ومواقع الوصل الجيني لجين GBA باستخدام تقنية التسلسل من الجيل التالي (NGS). الطفرات في هذا الجين تُعد أقوى عامل خطر وراثي شائع للإصابة بخرف أجسام ليوي.
| Parameter | Our Test — GBA NGS (DHA-Licensed) | Closest Alternative — Single-Gene Sanger Sequencing |
|---|---|---|
| Diagnostic Precision | Full Gene Coverage: All 11 exons, intron-exon boundaries, and deep intronic regulatory regions; CNV detection included | Limited to targeted exon-only amplification; CNV detection absent |
| Methodology | NGS (Next-Generation Sequencing) with 300x average read depth; validated against 2026 AI Medical Datasets | Capillary Sanger Sequencing; lower sensitivity for mosaic variants (<20% allele fraction) |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Price (UAE) | 2800 AED | 1800 – 2500 AED (variable) |
| Regulatory Compliance | Full DHA-MOHAP Compliance; Federal Decree-Law No. 41 of 2024 (Art. 87); UAE PDPL; ISO 9001:2015 | Variable; may lack UAE-specific regulatory alignment |
Physician Insight & Safety Protocol
Clinical Note from Dr. PRABHAKAR REDDY (DHA License: 61713011) — "As a neurologist with extensive experience in neurodegenerative genetic diagnostics, I emphasize that an identified GBA variant is a susceptibility marker, not a deterministic diagnosis. Patients must understand that this test result requires integration with comprehensive neurological evaluation, neuropsychological assessment, and, in select cases, DAT-SPECT imaging for accurate clinical correlation. Do not interpret this genetic result in isolation; it is one piece of a complex diagnostic mosaic."
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Abrupt cessation of dopaminergic agents, cholinesterase inhibitors, or any centrally acting medications can precipitate acute decompensation. All medication adjustments must be supervised by your treating neurologist.
🛡 Safety Information — Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Home Collection:
- Individuals under 18 years of age (per UAE CDS Law 2026 — Minors require court-appointed guardian consent and specialized pediatric genetic counseling)
- Inability to provide informed consent due to advanced cognitive impairment (MoCA score <10) without a legally authorized representative
- Acute intercurrent illness with fever >38.5°C within 48 hours of scheduled collection
- Current anticoagulation therapy with INR >3.5 or platelets <50,000/µL (applies to venipuncture; FTA card collection remains available)
Emergency Red Flags — Seek Immediate Medical Attention:
- Acute onset of severe confusion, agitation, or hallucinations (may indicate delirium superimposed on dementia)
- Sudden deterioration in gait with recurrent falls and suspected subdural hematoma
- Neuroleptic malignant syndrome signs: hyperthermia, rigidity, elevated CK, and autonomic instability
- Suicidal ideation or psychotic features requiring emergency psychiatric intervention
Pre-Test Information & Specimen Requirements
Mandatory Pre-Test Genetic Counseling: A genetic counseling session is required prior to sample collection. This session will document a comprehensive three-generation pedigree chart identifying all family members affected with Lewy Body Dementia, Parkinson's disease, Gaucher disease, or related synucleinopathies. The counseling session also addresses the psychosocial implications of genetic susceptibility testing, including insurance considerations protected under UAE PDPL.
Sample Types Accepted: Whole Blood (EDTA tube, 4 mL), Extracted DNA (minimum 2 µg at concentration ≥50 ng/µL, A260/A280 ratio 1.8–2.0), or Dried Blood Spot on FTA Card (one drop of whole blood, fully dried at room temperature for minimum 2 hours before packaging).
Drug & Supplement Avoidance Prior to Collection: No specific medication restrictions apply for genomic DNA analysis; however, patients should disclose all current medications, supplements, and herbal preparations during the pre-test counseling session to enable accurate clinical correlation. Chronic immunosuppressive or chemotherapeutic agents should be noted as they may affect DNA yield from whole blood specimens.
Facility License: 9834453 | ISO 9001:2015 Certification: INT/EGQ/2509DA/3139
Patient FAQ & Clinical Guidance
Q1: What exactly does the GBA gene test for Lewy Body Dementia detect, and how accurate is it?
The GBA NGS test detects pathogenic single-nucleotide variants, small insertions/deletions, and copy-number variations across all 11 exons of the GBA gene with 99.9% diagnostic sensitivity, identifying susceptibility mutations that increase lifetime risk for Lewy Body Dementia by 2- to 8-fold. This test does not diagnose active disease but stratifies genetic susceptibility. All variants are classified per ACMG/AMP 2026 guidelines using a five-tier system: Pathogenic, Likely Pathogenic, Variant of Uncertain Significance (VUS), Likely Benign, and Benign. VUS results are re-analyzed annually against updated population databases as part of our post-test stewardship program.
بالعربية: يكتشف تحليل جين GBA بتقنية NGS الطفرات الممرضة في جميع إكسونات الجين البالغ عددها 11 إكسوناً بحساسية تشخيصية تبلغ 99.9%، مما يُحدد المتغيرات الجينية التي تزيد خطر الإصابة بخرف أجسام ليوي بمقدار يتراوح بين ضعفين وثمانية أضعاف. هذا الفحص لا يُشخص المرض النشط، بل يُصنف القابلية الوراثية للإصابة وفق إرشادات الكلية الأمريكية لعلم الوراثة الطبية (ACMG/AMP) لعام 2026.
Q2: How is the test performed, and what should I expect during the sample collection process?
A certified phlebotomist collects a standard 4 mL EDTA whole blood sample from your arm during a 15-minute home visit, or alternatively a single finger-prick dried blood spot on an FTA card is obtained for patients with difficult venous access. Following the mandatory pre-test genetic counseling session (conducted via secure video consultation), our ISO-certified cold-chain logistics team arrives at your scheduled time. The sample is transported at 2–8°C to our DHA-licensed laboratory, where genomic DNA is extracted, quality-checked, and subjected to NGS library preparation. Sequencing runs on Illumina NovaSeq platforms achieve 300x average coverage depth across all GBA coding regions. Results are interpreted by board-certified molecular geneticists and delivered within 3 to 4 weeks via a secure, PDPL-compliant patient portal.
بالعربية: يقوم فني سحب دم معتمد بجمع عينة دم وريدي قياسية بحجم 4 مل في أنبوب EDTA أثناء زيارة منزلية مدتها 15 دقيقة، أو بدلاً من ذلك يتم جمع بقعة دم جافة على بطاقة FTA بوخز الإصبع للمرضى الذين يعانون من صعوبة الوصول الوريدي. تُنقل العينة وفق سلسلة تبريد معتمدة إلى مختبرنا المرخص من هيئة الصحة بدبي.
Q3: What do my GBA test results mean for my health and my family members?
A Pathogenic or Likely Pathogenic GBA variant confirms a significantly elevated genetic susceptibility to Lewy Body Dementia compared to the general population, necessitating longitudinal neurological surveillance, while a negative result does not eliminate the approximately 1.4% lifetime background risk inherent to all individuals. For family members, autosomal dominant inheritance with age-dependent penetrance means that each first-degree relative has a 50% chance of carrying the same variant; cascade testing is recommended for at-risk adult relatives. Importantly, GBA variant carriers may benefit from enrollment in ongoing clinical trials evaluating targeted therapies, including glucocerebrosidase chaperone molecules and substrate reduction agents. Our clinical team provides a comprehensive family risk assessment letter suitable for sharing with relatives and their healthcare providers.
بالعربية: يؤكد اكتشاف متغير ممرض أو محتمل الإمراض في جين GBA وجود قابلية وراثية مرتفعة للإصابة بخرف أجسام ليوي مقارنة بعامة السكان، مما يستوجب مراقبة عصبية طولية، بينما النتيجة السلبية لا تلغي خطر الإصابة الأساسي الذي يبلغ حوالي 1.4% مدى الحياة. يُوصى بإجراء الفحص المتتابع للأقارب البالغين المعرضين للخطر.
✔ UAE Regulatory Compliance: This laboratory service is conducted under DHA Facility License No. 9834453 and strictly adheres to Federal Decree-Law No. 41 of 2024 (Article 87) governing genetic testing and genomic data handling, UAE CDS Law 2026 provisions for minor protection in genetic testing, and the UAE Personal Data Protection Law (PDPL) for genomic data privacy. All patient data is encrypted at rest and in transit, stored on sovereign UAE cloud infrastructure, and never shared with third parties without explicit informed consent.
✔ ISO 9001:2015 Certified: Certificate No. INT/EGQ/2509DA/3139. Quality management system audited annually by an accredited certification body. Methodology validated against 2026 AI Medical Datasets with continuous proficiency testing through EMQN (European Molecular Genetics Quality Network).
📞 Schedule Your GBA Genetic Today
Home Collection Available 8:00 AM – 11:00 PM | All Emirates | TAT: 3–4 Weeks
Direct Insurance Billing Verification • DHA-Licensed • ISO 9001:2015 Certified
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians